These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1334 related items for PubMed ID: 24309530

  • 21. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
    Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M, GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry.
    Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
    [Abstract] [Full Text] [Related]

  • 22. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F.
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [Abstract] [Full Text] [Related]

  • 23. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
    Subari S, Baidoun F, Hreh M, Patnaik M, Hashmi S, Elliott M, Hogan W, Litzow M, Al-Kali A.
    Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
    [Abstract] [Full Text] [Related]

  • 24. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L, Greil R.
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [Abstract] [Full Text] [Related]

  • 25. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
    Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H.
    Cancer; 2009 Dec 15; 115(24):5746-51. PubMed ID: 19795507
    [Abstract] [Full Text] [Related]

  • 26. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.
    Asian Pac J Cancer Prev; 2015 Dec 15; 16(15):6627-32. PubMed ID: 26434886
    [Abstract] [Full Text] [Related]

  • 27. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP.
    Cancer; 2007 Jan 15; 109(2):265-73. PubMed ID: 17133405
    [Abstract] [Full Text] [Related]

  • 28. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.
    J Clin Oncol; 2011 May 20; 29(15):1987-96. PubMed ID: 21483003
    [Abstract] [Full Text] [Related]

  • 29. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
    Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.
    Hematol Oncol; 2012 Jun 20; 30(2):76-81. PubMed ID: 21387357
    [Abstract] [Full Text] [Related]

  • 30. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R, Fenaux P.
    Bull Cancer; 2011 Aug 20; 98(8):927-34. PubMed ID: 21821482
    [Abstract] [Full Text] [Related]

  • 31. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.
    Health Technol Assess; 2010 May 20; 14 Suppl 1():69-74. PubMed ID: 20507806
    [Abstract] [Full Text] [Related]

  • 32. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J, Tremblay D, Navada SC, Silverman LR.
    Leuk Lymphoma; 2023 Mar 20; 64(3):525-539. PubMed ID: 36370098
    [Abstract] [Full Text] [Related]

  • 33. The role of hypomethylating agents in the treatment of elderly patients with AML.
    Al-Ali HK, Jaekel N, Niederwieser D.
    J Geriatr Oncol; 2014 Jan 20; 5(1):89-105. PubMed ID: 24484723
    [Abstract] [Full Text] [Related]

  • 34. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF.
    Biol Blood Marrow Transplant; 2015 Oct 20; 21(10):1761-9. PubMed ID: 26055299
    [Abstract] [Full Text] [Related]

  • 35. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U, Study Alliance Leukemia Group.
    Leukemia; 2016 Mar 20; 30(3):555-61. PubMed ID: 26522083
    [Abstract] [Full Text] [Related]

  • 36. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.
    Leuk Res; 2014 Jul 20; 38(7):751-5. PubMed ID: 24836762
    [Abstract] [Full Text] [Related]

  • 37. [Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
    Huang YQ, Zhang XY, Wu SX, Guo XZ, Pan JX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec 20; 25(6):1641-1646. PubMed ID: 29262890
    [Abstract] [Full Text] [Related]

  • 38. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
    Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A.
    Am J Hematol; 2009 Oct 20; 84(10):688-9. PubMed ID: 19722261
    [No Abstract] [Full Text] [Related]

  • 39. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C, Schuster T, Peschel C, Götze KS.
    Ann Hematol; 2009 Mar 20; 88(3):213-9. PubMed ID: 18696067
    [Abstract] [Full Text] [Related]

  • 40. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.
    Cell Cycle; 2011 Jul 15; 10(14):2323-30. PubMed ID: 21654193
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.